|
zu MRK https://www.marketscreener.com/MERCK-AND-COMPANY-13611/news/… "The group is known for the quality of its R&D programs, typically managed internally from start to finish, while its competitors are more likely to favor the acquisition of the most promising biotechs to replenish their pipelines. This strategic choice is currently paying off and allows Merck to return almost all of its profits to the shareholders; of the $22 billion in free cash flow profits received over the past three years, only $1.5 billion has been spent on acquisitions." "Over the next five years, the group’s management expects to generate approximately $60 billion in cash profits. The first half of which will be used for dividends and the second half to finance additional acquisitions and/or share buybacks. Looking at the period 2016-2023, we can estimate an average cash profit of about $15 billion per year. The company’s current market capitalization ($211 billion) thus represents an a priori very reasonable multiple of 14 times this earnings capacity." |
|
| aus der Diskussion: | Timburgs Langfristdepot - Start 2012 |
| Autor (Datum des Eintrages): | clearasil (20.11.19 11:39:21) |
| Beitrag: | 40,308 von 56,684 (ID:61969775) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |